The offering removes near-term cash runway risk and adds a high-quality strategic investor (Lilly), but dilutes existing holders. Watch for clinical data readouts on ABS-201 in alopecia/endometriosis as the primary catalyst. The at-market pricing and Lilly participation suggest the stock may hold near $7.41 near-term, but further dilution risk remains if additional capital is needed before pipeline value inflection.
Price Chart
Executive Summary
Absci Corp priced a $100 million underwritten offering of 13.5 million shares at $7.41 per share, with Eli Lilly committing $40 million. Net proceeds of ~$93.5 million will fund advancement of lead candidate ABS-201 in alopecia and endometriosis, plus working capital. The offering dilutes existing holders by ~6-9% but provides a cash runway and strategic validation from a top pharma partner.
Key Facts
- Offering of 13,495,277 shares at $7.41/share, gross proceeds ~$100 million
- Eli Lilly & Company allocated $40 million of the offering (5,398,111 shares)
- Net proceeds estimated at ~$93.5 million after underwriting discounts and expenses
- Proceeds to fund ABS-201 (anti-PRLR antibody) for androgenetic alopecia and endometriosis
- Joint book-runners: Jefferies, J.P. Morgan, TD Cowen, Guggenheim Securities
- Closing expected June 25, 2026; 60-day lock-up for insiders
Financial Impact
Dilution of ~13.5M new shares (approximately 6-9% of pre-offering shares outstanding) raising ~$93.5M net; strategic investment from Lilly provides validation
Risk Factors
- ~6-9% dilution from new shares
- Clinical-stage biotech: ABS-201 has no approved products and faces development risk
- Cash burn rate may require additional financing before revenue generation
- Potential overhang from the 60-day lock-up expiration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-281143 |
| Document: d139233d8k.htm | 0001193125-26-281143 |
| Document: d139233dex991.htm | 0001193125-26-281143 |
| Document: d139233dex51.htm | 0001193125-26-281143 |
| Document: 0001193125-26-281143-index-headers.html | 0001193125-26-281143 |
| Document: 0001193125-26-281143-index.html | 0001193125-26-281143 |
| Document: 0001193125-26-281143.txt | 0001193125-26-281143 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $9.50 $9.99 | ▲ +5.16% | ▲ +5.60% | $10.64 (+12.00%) |
Jul 6, 2026 16w ago | Insider Buy | $11.33 $10.23 | ▼ −9.71% | ▼ −10.26% | $10.64 (−6.09%) |
Jun 24, 2026 17w ago | 8-K | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $10.64 (+4.21%) |
Jun 24, 2026 17w ago | 424B5 | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $10.64 (+4.21%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.64 (+5.61%) |
Jun 24, 2026 17w ago | 8-K | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.64 (+5.61%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.64 (+5.61%) |
Apr 23, 2026 26w ago | Press Release | $3.94 $4.98 | ▲ +26.27% | ▲ +25.36% | $10.64 (+170.05%) |
Apr 22, 2026 26w ago | DEFA14A | $3.97 $4.71 | ▲ +18.64% | ▲ +17.16% | $10.64 (+168.01%) |
Mar 24, 2026 30w ago | Press Release | $2.92 $3.15 | ▲ +7.88% | ▲ +8.12% | $10.64 (+264.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers